Off-Label Use of Immunotherapy: Is It Allowed? — What Indian Law Permits, and What Your Insurer Will Say

Off-label use means an approved medicine is given for a cancer, stage, line, dose or age group that is not listed in the prescribing information approved for it in India. The medicine is licensed and legally sold. That particular use is simply not the one the regulator assessed.

The word sounds irregular. It is not. Off-label prescribing is ordinary practice across medicine, and in oncology it is common — particularly in rare cancers, where no company has filed for an Indian indication because the numbers were never there to run the trial. What makes it worth a page of its own is the second half of the story: off-label use is one of the most frequent reasons an Indian health-insurance claim for immunotherapy is refused, and families almost always discover this after the first cycle rather than before it.

This page is informational. It explains how off-label use is regulated and funded in India. It does not offer access to any medicine, does not recruit anyone into any study, and cannot promise that an insurer will pay. Whether off-label treatment is appropriate for you is a clinical judgement for your treating oncologist and a tumour board, on your reports — and for most patients the answer is that it is not.

In practice, yes. Indian drug regulation governs how a medicine is manufactured, imported, sold and advertised. It does not list the conditions a registered doctor may prescribe an approved medicine for. Prescribing off-label is a clinical decision, and the accountability for it sits with the prescriber.

• The approval is about the product, not the prescription. When CDSCO approves a medicine it approves what may be marketed and for which indication. A registered medical practitioner making a treatment decision for an individual patient is working under professional conduct regulations administered by the National Medical Commission and the state medical councils, not under the marketing approval.
• The company may not promote the unapproved use. This is the line that is enforced. A manufacturer cannot advertise or promote a medicine for an indication it has not been approved for in India. Nothing on this page describes an off-label use as recommended, and no medicine is named against one.
• The prescriber has to be able to justify it. Off-label does not mean unaccountable. The expectation is a defensible clinical rationale, a note in the record explaining why the approved options were not appropriate, and consent that is specific about the off-label status.
• Consent has to name it explicitly. A general treatment consent form is not enough. The document should state in plain language that the medicine is not approved in India for this use, what is expected, what the risks are, and what the alternatives are — including the option of not treating.
• A documented tumour board decision is the strongest protection. For the patient, because it is better medicine than one doctor deciding alone. For the claim, because it answers the insurer's first question — who decided this, and on what basis.
• Ask what is approved in India specifically. Tissue-agnostic and biomarker-led approvals differ between countries. A use routinely funded in another country can still be off-label here, and it is the Indian wording an insurer will read.

Regulatory positions change. Confirm the current CDSCO status for the specific medicine and indication with your treating team before you act on anything here, and ask for the answer in writing.

Three different things get called the same thing in conversation. Approved use is the medicine given as CDSCO licensed it. Off-label use is the same licensed medicine used outside that wording, bought at market price. A trial is research, with free study drug and ethics oversight.

Off-label is often described to families as the affordable route to immunotherapy. It is usually the most expensive one, because the drug cost lands on the household and the insurer has a ready-made reason to decline. If cost is the real obstacle, a registered study is a different conversation — Is Treatment Free in a Clinical Trial? sets out exactly what a sponsor does and does not pay for.

Most often in rare cancers with no registered Indian indication, and in biomarker-led decisions where a tumour carries a marker that a labelled cancer shares. It also arises with doses, schedules, later lines and combinations that sit outside the approved wording, even when the cancer itself is on-label.

• Rare cancers with no Indian indication. The commonest scenario, and the reason this question is searched at all. If no company applied, there is no label to be on, however reasonable the treatment may look.
• Biomarker-led reasoning across organs. A tumour shown to be mismatch-repair deficient or microsatellite instability high may be treated on the strength of that marker rather than the organ it started in. Whether that is on-label in India depends on the exact Indian wording for that medicine, which is worth checking rather than assuming.
• A different dose or schedule. Flat dosing where the label is weight-based, or a longer interval between cycles, is off-label even when the cancer and the medicine are approved together.
• A later line than the label covers. An indication approved for first-line use does not automatically cover use after two previous lines, and insurers read that distinction closely.
• Combinations. Two medicines can each be approved while the combination is not. This is a common and easily missed reason for a refusal.
• Populations the label excludes. Age groups, organ function thresholds and autoimmune history sit at the highest-scrutiny end and need the clearest documentation.
• Continuing past the studied duration. Treating beyond the period the approval is based on is a decision in its own right, and should have its own review point rather than drifting on by default.

Often it will not. Indian health policies carry a standardised exclusion for unproven or experimental treatment, and insurers routinely place off-label use inside it. Cover is decided case by case on the papers you submit, which is why written pre-authorisation before the first dose matters so much.

This is the part of the page that costs families money when it is skipped. An off-label plan started on a verbal assurance, with the paperwork left until discharge, is a claim already in trouble. The order of operations is the whole game: build the file first, submit it first, get the answer in writing first, and only then decide whether to start.

• Know the exclusion that will be quoted at you. Indian policies use a standardised set of exclusions, one of which covers unproven treatment — treatment not supported by sufficient medical documentation of effectiveness. Off-label use is the classic candidate. Ask your insurer, in writing, how they apply that clause to the specific medicine and indication proposed for you.
• Pre-authorisation is the whole exercise. Send the histopathology report, the biomarker report where there is one, the previous lines of treatment, the tumour board note, and the guideline the use rests on. Ask for a written decision before the first dose, not a counter conversation.
• Name a guideline body, not a doctor. A submission that points to a recognised body such as NCCN, ESMO or ASCO recognising the use is assessed differently from one that says the treating doctor recommends it. Both may be true. Only one reads as documentation.
• Government schemes pay against packages. Aarogyasri and similar schemes reimburse defined packages at fixed ceilings. If the medicine or indication is not in the package list, it is not payable, regardless of how sound the clinical case is. Check the package list before starting, not after.
• Corporate and retail policies differ. Employer group cover often has different wording from a retail policy. Ask HR or the third-party administrator for the actual clause, not a summary.
• Get any refusal in writing, and read the reason. A refusal on paperwork grounds can be answered with paperwork. A refusal on the unproven-treatment exclusion is a different argument. Insurers have an internal grievance process, and the Insurance Ombudsman sits beyond it.
• Any figure is indicative only, as of August 2026. Drug prices, biosimilar availability and assistance programmes all move. Ask for a written estimate for your own regimen rather than working from a number heard elsewhere.

Seven steps, in this order: confirm it really is off-label, ask what the use rests on, get the tumour board decision written down, sign a consent that names the off-label status, apply for written pre-authorisation before the first dose, plan for a refusal, and fix a review point and stop rule.

1. 1

   Confirm that it really is off-label

   Ask the treating oncologist one direct question: is this medicine approved in India for my cancer and my situation, or is it being used outside that approval? Ask for the answer in the case notes. Families most often learn the answer months later, from a claim rejection letter.

2. 2

   Ask what the use rests on, and what it does not

   Off-label is not a synonym for guesswork. Ask which guideline body recognises the use, whether it rests on a biomarker such as mismatch-repair deficiency or high microsatellite instability, and what the evidence does not yet show. A doctor who can answer the third question is the one to trust.

3. 3

   Take it to the tumour board and get the decision written down

   A documented multidisciplinary decision is better medicine and, separately, the strongest single document you will hold when an insurer asks who decided and on what basis. At CION every plan goes to a tumour board rather than resting on one doctor's opinion.

4. 4

   Sign a consent that names the off-label status

   The consent should say plainly that the medicine is not approved in India for this use, what the expected benefit and the risks are, what the alternatives are, and that not treating, or continuing with best supportive care, is a legitimate option rather than a failure.

5. 5

   Apply for written pre-authorisation before the first dose

   Send the histopathology report, the biomarker report, the previous lines of treatment, the tumour board note and the guideline reference. Ask for the insurer's decision in writing. Nothing said across a hospital counter counts as pre-authorisation when the claim is assessed.

6. 6

   Plan for a refusal before it arrives

   Ask what the funded alternative would be, what the medicine would cost you if you paid for it, whether a biosimilar is marketed in India, whether the manufacturer runs a patient assistance programme, and whether a registered trial covers the same ground. Any figure quoted to you is indicative only, as of August 2026.

7. 7

   Fix the review point and the stop rule in advance

   Agree how response will be assessed and when, and agree what happens if there is no benefit. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION. Off-label treatment with no agreed stop rule turns into an open-ended bill.

Immunotherapy at CION is given as day care, and every plan is taken to a tumour board rather than resting on a single opinion. If a registered study is the route you want to explore instead, How to Find an Immunotherapy Clinical Trial in India explains where trials are actually listed, and Travelling to Another City for a Clinical Trial covers what relocating for one really involves.

It does not mean the treatment is proven, and it does not automatically mean it is unproven either. It does not mean your doctor is doing something irregular. It does not mean the treatment is free or discounted. And it does not mean anyone can promise benefit.

• It does not settle the evidence question either way. A label reflects what a company applied for and what a regulator assessed. Some off-label uses rest on solid published work and guideline recognition. Others rest on very little. Ask which one you are being offered, and ask what the evidence does not show.
• It is not research, and carries none of research's protections. A trial brings ethics-committee review, a protocol, monitoring, free study drug and required medical management of trial-related injury. Off-label use brings none of that, and the bill comes to you.
• It is not the cheap route. This is the most common misunderstanding in this whole area. Off-label is frequently the most expensive path a family can take, precisely because the insurer has grounds to decline.
• It does not mean your oncologist is acting improperly. Off-label prescribing is routine across medicine when it is justified, documented and consented to. The questions to ask are about rationale and paperwork, not about good faith.
• It does not make benefit certain. Response to immunotherapy occurs in a proportion of patients even within approved indications, and outside them the evidence is usually thinner. Anyone describing an off-label plan as certain to work is describing something no one can know.
• It does not cover cell therapy. CION does not provide CAR-T or cell therapy. Those requests are handled as referral and orientation only, and nothing on this page should be read as an offer of such treatment.
• Not treating remains a real option. For some situations best supportive care is a legitimate choice rather than a failure, and it deserves to be discussed openly and early — not raised only once the money has run out.

Off-label use is one of three ways families reach a medicine they cannot otherwise afford. The other two are registered clinical trials and travelling to a centre that runs one. These pages cover what each route really costs and how each one is entered.

• Is Treatment Free in a Clinical Trial? — what a sponsor pays for, what stays on your bill, and what reimbursement an ethics committee can approve.
• How to Find an Immunotherapy Clinical Trial in India — where studies are actually registered, and why a referral from your treating oncologist is the only route in.
• Travelling to Another City for a Clinical Trial — the visit schedule, the accommodation gap, and the questions to settle before a family relocates.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment and response monitoring fit together as one pathway.

No Rushed Decisions. Nothing Promised That Cannot Be Delivered.

Every plan is reviewed by a tumour board, and every family is told what is certain and what is not before treatment starts.